Table 4 Long-term anti-HBs titre and proportion of individuals below 10 IU/l by time interval between the administration of the second and the third dose.
From: Factors influencing long-term persistence of anti-HBs after hepatitis B vaccination
Time 2nd–3rd dose (months) | Antibody titre | <10 IU/l | |||
|---|---|---|---|---|---|
GMT | GSD | % | 95% CI | ||
Cohort 1 | |||||
5.51– 6.00 | 8.14 | 5.40 | 56.4% | 51.4% | 61.4% |
6.01–6.50 | 9.52 | 5.31 | 52.7% | 49.8% | 55.7% |
6.51–7.00 | 10.10 | 5.66 | 52.4% | 49.3% | 55.4% |
7.01–7.50 | 10.42 | 5.67 | 51.6% | 48.3% | 54.9% |
7.51–8.00 | 11.72 | 5.39 | 49.5% | 46.1% | 52.8% |
8.01–8.50 | 12.73 | 5.77 | 46.3% | 42.1% | 50.5% |
8.51–9.00 | 13.83 | 6.27 | 47.0% | 41.5% | 52.5% |
9.01–9.50 | 13.94 | 5.83 | 40.0% | 32.2% | 48.3% |
Cohort 2 | |||||
4.51–5.00 | 93.17 | 6.59 | 11.2% | 8.4% | 14.6% |
5.01–5.50 | 104.47 | 6.52 | 11.9% | 10.3% | 13.7% |
5.51–6.00 | 105.73 | 6.55 | 11.4% | 9.5% | 13.4% |
6.01–6.50 | 101.53 | 6.93 | 13.4% | 10.7% | 16.5% |
6.51–7.00 | 95.45 | 6.84 | 13.5% | 9.5% | 18.5% |
7.01–7.50 | 87.98 | 8.34 | 15.7% | 9.8% | 23.5% |
